Celldex Therapeutics (CLDX) Depreciation & Amortization (CF) (2010 - 2026)

Celldex Therapeutics' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $854000.0 for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 1.5% year-over-year to $854000.0 in Q1 2026; TTM through Mar 2026 was $3.4 million, a 3.0% increase from a year earlier, with the FY2025 full-year figure at $3.4 million, up 6.39% from the prior year.
• Depreciation & Amortization (CF) climbed to $854000.0 in Q1 2026 per CLDX's latest filing, from $816000.0 in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $873000.0 in Q2 2025 and bottomed at $671000.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $786000.0 (2024), against an average of $783235.3.
• Across the five-year window, Depreciation & Amortization (CF) retreated 13.38% in 2022 and rose 14.31% in 2023, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $673000.0 in 2022, then rose by 12.78% to $759000.0 in 2023, then gained by 7.91% to $819000.0 in 2024, then retreated by 0.37% to $816000.0 in 2025, then increased by 4.66% to $854000.0 in 2026.
• Per Business Quant, the three latest CLDX Depreciation & Amortization (CF) figures stand at $854000.0 (Q1 2026), $816000.0 (Q4 2025), and $824000.0 (Q3 2025).